多灶性和弥漫浸润性乳腺癌是需进一步改进诊疗策略的高致死亚组
基于数十年前瞻性记录的病例,利用影像生物标志物按起源部位对乳腺癌分型,发现多数乳腺癌死亡(71%)发生在少数乳腺癌(45%)中;多灶性腺泡腺癌、弥漫浸润性导管起源癌和间叶杂交细胞起源乳腺恶性肿瘤的死亡率显著高于单灶浸润性癌。作者提出需重新评估组织病理学术语、加强多模态影像和多学科管理并应用影像引导大格式组织病理学。
要点
- 多数乳腺癌死亡(71%)发生于少数乳腺癌(45%),提示致死性亚型集中。
- 多灶性腺泡腺癌、弥漫浸润性导管起源癌和间叶杂交细胞起源肿瘤死亡率高于单灶浸润性癌。
- 作者提出需重新评估乳腺癌组织病理学术语并加强多模态影像与多学科管理。
核心结论
- 多数乳腺癌死亡(71%)发生在少数乳腺癌(45%)中,多灶性腺泡腺癌(13.1%)、弥漫浸润性导管起源癌(24%)和间叶杂交细胞起源乳腺恶性肿瘤(33.7%)的乳腺癌死亡率显著高于单灶浸润性癌(6.1%)。
研究设计与样本
- 基于数十年前瞻性记录的病例研究,利用影像生物标志物按起源部位对乳腺癌分型,比较不同亚型的乳腺癌死亡率。
诊断标准与关键数值
- 多灶性腺泡腺癌乳腺癌死亡率为13.1%。
- 弥漫浸润性导管起源癌乳腺癌死亡率为24%。
- 间叶杂交细胞起源乳腺恶性肿瘤乳腺癌死亡率为33.7%。
- 单灶浸润性乳腺癌乳腺癌死亡率为6.1%。
临床应用与阅片要点
- 作者提出需重新评估当前不完善的乳腺癌组织病理学术语,特别关注弥漫性乳腺癌亚型。
- 作者提出需加强多模态影像和多学科管理。
- 作者提出需应用影像引导大格式组织病理学。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Physicians treating breast cancer patients often wonder why this dreaded disease is still fatal in some women despite our best diagnostic and therapeutic efforts. Our own studies on prospectively documented cases spanning several decades have given us new insights for approaching this problem. By using imaging biomarkers to classify breast cancer subtypes according to their apparent site of origin, we found that a majority of breast cancer deaths (71%) occur in a minority of breast cancers (45%). Breast cancer deaths are significantly more likely to occur in women with multifocal acinar adenocarcinoma of the breast, AAB (13.1%), diffusely invasive breast cancers of ductal origin, DAB (24 %) and breast malignancies of mesenchymal hybrid cell origin, BCMO (33.7%) compared with women having unifocal invasive breast cancers (6.1%). Preventing more of these fatal events will require a re-evaluation of the current imperfect histopathologic terminology of breast cancer with special attention to the diffuse breast cancer subtypes, intensification of multimodality imaging and multidisciplinary management, as well as application of image guided large format histopathology.
引用
- Tabár, Dean, Tucker, et al. Multifocal and diffusely infiltrating breast cancers are highly fatal subgroups needing further improvement in diagnostic and therapeutic strategies. Eur J Radiol. 2023. PMID: 37163829. doi:10.1016/j.ejrad.2023.110854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。